Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00441441 · ClinicalTrials.gov registry record · Phase 3

A 12-Week Study To Assess The Safety Of Fluticasone Propionate/Salmeterol 100/50 Hydrofluoroalkane (HFA) Versus Fluticasone Propionate 100 HFA In Children With Asthma

A Phase 3 study, sponsored by GlaxoSmithKline.

Completed
Registry status
Phase 3
Development phase
351
Enrollment target

NCT00441441: Completed Phase 3 study, sponsored by GlaxoSmithKline.

NCT00441441 is a Phase 3 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 351 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (55% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00441441, a Phase 3 study, has completed, sponsored by GlaxoSmithKline.

COMPLETED
Registry status
Phase 3
Development phase
351 participants
Enrollment target

Study Summary

This study is to assess the safety of an investigational drug in children 4 to 11 years of age who have asthma. The subjects will attend 7 clinic visits, of which up to 3 will be in the morning, and have lung function tests performed.

Primary Outcome

Adverse Events reported by the Investigator and judged by the Investigator to be possibly related to study drug, categorized by the Medical Dictionary for Regulatory Activities (MeDRA), were reported. ECG, electrocardiogram. QTc (corrected QT interval) and QT represent intervals on an ECG.

Interventions

  • DRUG fluticasone propionate
  • DRUG fluticasone propionate/salmeterol

Trial Details

FieldValue
Enrollment Target 351 participants
Start Date 2007-02
Est. Completion 2008-01
Phase Phase 3
GlaxoSmithKline

1,345 total trials

What the finished NCT00441441 record still lists

NCT00441441 is an interventional study that assigns participants to a tested intervention. The registered 351 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (55% lower).

The record links to 0 conditions, and to 2 interventions - of which fluticasone propionate is the first listed.

NCT00441441 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00441441 about?

NCT00441441 is a clinical study titled "A 12-Week Study To Assess The Safety Of Fluticasone Propionate/Salmeterol 100/50 Hydrofluoroalkane (HFA) Versus Fluticasone Propionate 100 HFA In Children With Asthma". This study is to assess the safety of an investigational drug in children 4 to 11 years of age who have asthma. The subjects will attend 7 clinic visits, of which up to 3 will be in the morning, and have lung function tests performed.

What is the current status of trial NCT00441441?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 351 participants. The study started on 2007-02. Estimated completion is 2008-01.

What interventions are being tested in trial NCT00441441?

The interventions under investigation include: fluticasone propionate (DRUG), fluticasone propionate/salmeterol (DRUG).

Who is sponsoring clinical trial NCT00441441?

This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00441441's enrollment target sits among peer trials

351 1033rd of 2000 higher than 967 of 2,000 other Phase 3 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT06241456 · 351 participants · Phase 1

    FT825/ONO-8250, an Off-the-Shelf, HER2 CAR-T, With or Without Monoclonal Antibodies in Advanced Solid Tumors

  • NCT06576726 · 351 participants

    Sensorimotor and Psychosocial Trajectories in Adolescents With Tic Disorder

  • NCT07043400 · 351 participants · Phase 3

    A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

  • NCT07261423 · 351 participants · NA

    Pollution Intervention to Impact Kids Asthma Study

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00441441, the US trial registry maintained by the National Library of Medicine. NCT00441441 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.